Gotham Asset Management’s Adaptive Biotechnologies ADPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.48M Buy
120,258
+45,526
+61% +$1.12M 0.01% 1084
2026
Q2
$1.6M Sell
74,732
-16,013
-18% -$245K ﹤0.01% 1217
2026
Q1
$1.26M Sell
90,745
-50,011
-36% -$797K ﹤0.01% 1244
2025
Q4
$2.29M Buy
140,756
+13,692
+11% +$223K 0.01% 999
2025
Q3
$1.9M Buy
127,064
+55,177
+77% +$672K 0.01% 1018
2025
Q2
$837K Buy
71,887
+61,194
+572% +$556K 0.01% 1189
2025
Q1
$79.4K Buy
+10,693
New +$82.2K ﹤0.01% 1517
2023
Q3
– Sell
-16,073
Closed -$108K – 1315
2023
Q2
$108K Sell
16,073
-30,210
-65% -$225K ﹤0.01% 1268
2023
Q1
$409K Buy
46,283
+14,616
+46% +$129K 0.01% 1029
2022
Q4
$242K Sell
31,667
-19,816
-38% -$154K 0.01% 1093
2022
Q3
$367K Sell
51,483
-723
-1% -$6.81K 0.01% 926
2022
Q2
$422K Buy
+52,206
New +$459K 0.01% 839

Other funds holding ADPT

Gotham Asset Management's ADPT Position: Q3 2026 in Review

Gotham Asset Management increased its Adaptive Biotechnologies (ADPT) stake by 61% in Q3 2026, buying an estimated $1.12M and bringing the position to 120,258 shares worth $3.48M. The position accounts for 0.01% of the portfolio, ranked #1084.

Gotham Asset Management first reported a position in ADPT in Q2 2022 and has held it in 12 quarters since. 334 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.

  • Gotham Asset Management held 120,258 shares of Adaptive Biotechnologies worth $3.48M as of Q3 2026.
  • Gotham Asset Management bought 45,526 Adaptive Biotechnologies shares in Q3 2026, an estimated $1.12M.
  • Adaptive Biotechnologies made up 0.01% of Gotham Asset Management's portfolio in Q3 2026, its #1084 holding.
  • Gotham Asset Management first reported a position in Adaptive Biotechnologies in Q2 2022 and has held it in 12 quarters since.
  • 334 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.

Based on Gotham Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.